 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
18 News |  |
- | MOD-5023 / OPKO Health, LeaderMed
Trial completion, Trial completion date: A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (clinicaltrials.gov) - Jul 11, 2019
P1/2, N=27, Completed, Sponsor: Opko Biologics
Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> Sep 2018
- | MOD-5023 / OPKO Health, LeaderMed
Enrollment closed, Trial completion date: A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (clinicaltrials.gov) - Jan 4, 2019
P1/2, N=27, Active, not recruiting, Sponsor: Opko Biologics
Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> Sep 2018 Recruiting --> Active, not recruiting | Trial completion date: Sep 2018 --> Apr 2019
- | MOD-5023 / OPKO Health, LeaderMed
Trial completion date, Trial primary completion date: A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (clinicaltrials.gov) - May 4, 2018
P1/2, N=24, Recruiting, Sponsor: Opko Biologics
Recruiting --> Active, not recruiting | Trial completion date: Sep 2018 --> Apr 2019 Trial completion date: May 2017 --> Sep 2018 | Trial primary completion date: Mar 2017 --> Sep 2018
- || MOD-5023 / OPKO Health, LeaderMed
Trial completion, Enrollment change: A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male (clinicaltrials.gov) - May 4, 2018
P1, N=32, Completed, Sponsor: Opko Biologics
Trial completion date: May 2017 --> Sep 2018 | Trial primary completion date: Mar 2017 --> Sep 2018 Recruiting --> Completed | N=64 --> 32
- ||| MOD-5023 / OPKO Health, LeaderMed
Enrollment open, Trial primary completion date: A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male (clinicaltrials.gov) - Nov 13, 2017
P1, N=64, Recruiting, Sponsor: Opko Biologics
Recruiting --> Completed | N=64 --> 32 Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2017 --> Mar 2018
- ||| MOD-5023 / OPKO Health, LeaderMed
New P1 trial: A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male (clinicaltrials.gov) - Sep 29, 2016
P1, N=64, Not yet recruiting, Sponsor: Opko Biologics
- MOD-5023 / OPKO Health, LeaderMed
Trial primary completion date: A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=24, Recruiting, Sponsor: Opko Biologics
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2017 --> Mar 2018 Trial primary completion date: May 2016 --> Mar 2017
- | MOD-5023 / OPKO Health, LeaderMed
Enrollment open: A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (clinicaltrials.gov) - Nov 27, 2015
P1/2, N=24, Recruiting, Sponsor: Opko Biologics
Trial primary completion date: May 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- MOD-5023 / OPKO Health, LeaderMed
New P1/2 trial: A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (clinicaltrials.gov) - Apr 16, 2015
P1/2, N=24, Not yet recruiting, Sponsor: Opko Biologics